{"title":"Phytochemical Characterisation, Antioxidant Profiling, and Wound Healing Potential of Aqueous and Ethanolic Extracts of Michelia champaca Linn. (Magnoliaceae): An Integrative In Vitro and In Vivo Study","authors":"Nikhil Kumar, Jyoti Nanda Sharma","doi":"10.1007/s12247-026-11084-x","DOIUrl":"10.1007/s12247-026-11084-x","url":null,"abstract":"<div><h3>Background</h3><p>Chronic and acute wounds impose a formidable global health burden. <i>Michelia champaca</i> Linn. (Magnoliaceae), widely distributed across tropical Asia, is ethnomedicinally valorised for wound management and anti-inflammatory applications; yet rigorous pharmacological substantiation remains incomplete.</p><h3>Objective</h3><p>To perform comprehensive phytochemical characterisation—Total phenolic content (TPC), total flavonoid content (TFC), DPPH antioxidant activity, TLC, and HPTLC fingerprinting—of aqueous (AEMC) and ethanolic (EEMC) leaf extracts of <i>M. champaca</i>, and to evaluate the wound-healing efficacy of their formulated herbal ointments in a validated in vivo model.</p><h3>Methods</h3><p>Leaf powder was extracted via Soxhlet apparatus (distilled water; 95% ethanol). Physicochemical standardisation followed WHO guidelines. Folin quantified TPC–Ciocalteu assay (mg GAE/g), TFC by aluminium chloride colourimetry (mg QE/g), and antioxidant capacity by DPPH radical scavenging. HPTLC fingerprinting used a Toluene:ethyl Acetate:formic Acid: methanol (3:6:1.6:0.4) system. Herbal ointments (2% w/w, fusion method) were evaluated in a 10 mm biopsy punch excision wound model in male Albino Wistar rats (n = 5/group) over 14 days, benchmarked against Povidone-Iodine (10% w/w). Two-way ANOVA with Tukey's post hoc test analysed the data (p < 0.01).</p><h3>Results</h3><p>EEMC exhibited superior TPC (494.85 ± 18.40 mg GAE/g) and DPPH inhibition (72.36 ± 6.41%) versus AEMC (86.39 ± 3.43 mg GAE/g; 51.14 ± 8.22%). HPTLC confirmed rutin (0.175–0.225%) and caffeic acid (0.086–0.093%) in both extracts. EEOMC achieved 100% wound closure by Day 12, comparable to the standard, while AEOMC completed closure by Day 14 (p < 0.01 vs. vehicle control).</p><h3>Conclusion</h3><p><i>M. champaca</i> leaf extracts demonstrate potent wound healing activity attributable to their phenolic–flavonoid constituents. The ethanolic formulation is a promising botanical wound-care candidate warranting further mechanistic and histopathological validation.</p></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"22 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149234505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Evaluation of the Efficacy of BiSCaO Ointment Formulated with Eggshell Derived Calcium Oxide for the Treatment of Pseudomonas aeruginosa in a Rat Wound Infection Model","authors":"Souad Cheraitia, Soumia Keddari, Ahlem Laissouf, Meriem Mokhtar, Mokhtaria Yasmina Boufadi, Abla Bouhend, Djahira Hamed","doi":"10.1007/s12247-026-11112-w","DOIUrl":"10.1007/s12247-026-11112-w","url":null,"abstract":"<div><h3>Background</h3><p>Wound infections caused by <i>Pseudomonas aeruginosa</i> pose a major therapeutic challenge due to the emergence of strains that are resistant to multiple antibiotics. This study aims to utilize chicken eggshells as a sustainable source of calcium oxide (CaO) and to evaluate the efficacy of BiSCaO (Bioshell Calcium Oxide) ointments in the treatment of infected wounds in rats.</p><h3>Methods</h3><p>Eggshells were calcined at 900°C to produce CaO with a yield of 56.06%. X-ray fluorescence (XRF) and X-ray diffraction (XRD) analyses confirmed a high calcium content and the nearly complete conversion of CaCO₃ to CaO. Ointments containing 0.04, 0.2, 1, and 5 wt% BiSCaO were prepared. The <i>in vivo</i> study was conducted on rats with 10 mm wounds infected with <i>P. aeruginosa</i>. The wounds were treated daily for 3 days with either petroleum jelly (Vaseline), 2% fusidic acid, or one of the BiSCaO ointments, followed by saline-only cleaning from Day 4 to Day 9. The efficacy of the treatment was assessed based on bacterial load, wound healing, and histological analysis.</p><h3>Results</h3><p>BiSCaO ointments exhibited dose-dependent activity. The 5 wt% formulation showed the highest antibacterial activity, comparable to that of fusidic acid, but with signs of a cytotoxic effect characterized by minimal granulation tissue formation and limited neovascularization. In contrast, the 1 wt% BiSCaO ointment yielded the best overall results, with a significant reduction in bacterial load, nearly complete healing by day 9, and optimal tissue regeneration.</p><h3>Conclusions</h3><p>These results suggest that eggshells are a sustainable source of high-purity CaO and that the 1 wt% BiSCaO ointment is a promising alternative for the topical treatment of wounds infected with <i>P. aeruginosa</i>.</p><h3>Graphical Abstract</h3><div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"22 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149234504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ambar B. Marne, Ujwal Havelikar, Sopan Nangare, Ashwini S. Deshpande, Darshan R. Telange, Meghanath B. Shete
{"title":"Development and Optimization of a Resveratrol-Loaded Transferosomal Carbopol Gel for Enhanced Topical Delivery: In Vitro, Ex Vivo, and In Vivo Evaluation","authors":"Ambar B. Marne, Ujwal Havelikar, Sopan Nangare, Ashwini S. Deshpande, Darshan R. Telange, Meghanath B. Shete","doi":"10.1007/s12247-026-11130-8","DOIUrl":"10.1007/s12247-026-11130-8","url":null,"abstract":"<div><p><i>Cutaneous leishmaniasis (CL)</i> is one of the neglected tropical diseases that requires safer, more effective topical therapies. Although resveratrol (RVT) possesses reported in vitro antileishmanial activity, its poor aqueous solubility, instability, and limited skin penetration may restrict its topical application. Therefore, the present study aimed to develop and optimize RVT-loaded transferosomes (RVT-TFs) using the ethanol-injection method and further dispersed in Carbopol 934P gel (RVT-TFs-G). In brief, a 3<sup>3</sup> Box–Behnkendesign was employed to achieve an optimized formulation with particle size (PS) of 180.1 ± 1.9 nm, polydispersity index (PDI) 0.234 ± 0.01, % entrapment efficiency (EE) 80.9 ± 0.51%, drug loading (DL) 8.57 w/w, and zeta potential (ZP) of- 18.3 ± 1.2 mV. Furthermore, FTIR, DSC, and XRD analyses supported the incorporation of RVT into the lipid vesicular matrix and a reduction in its crystalline character. Additionally, TEM analysis revealed predominantly spherical vesicles with an average vesicle size of approximately 170.3 nm. It showed sustained release of RVT from optimized RVT-TFs as 86.2 ± 5.17% (<i>p</i> < 0.0001) in 24 h. RVT-TFs-G demonstrated a skin-compatible pH and suitable rheological properties for effective dermal application. Ex-vivo permeation studies demonstrated sustained RVT release of 70.81 ± 2.61% over 24 h (<i>p</i> < 0.0001) from RVT-TFs-G compared with RVT solution. Furthermore, skin irritation and histopathological studies confirmed non-irritant properties, and cytotoxicity studies on L929 murine fibroblast cell lines indicated acceptable cellular safety. In addition, stability studies supported the physicochemical integrity of the optimized system. Concisely, these findings support RVT-TFs-G as a promising topical RVT delivery platform with enhanced ex vivo skin permeation and acceptable physicochemical and dermal compatibility. However, direct antileishmanial efficacy and skin-retention studies are required before its therapeutic applicability in CL can be established.</p><h3>Graphical abstract</h3><div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"22 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149234475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ziyad Tariq Muhseen, Hussen Hazim Al-Ghanini, Roaa A. Humaidan, Zahraa Yousif Al-Hajjaj, Ola H. Fadhil
{"title":"Integrated Machine Learning and Structure-Based Computational Discovery of Natural Product Inhibitors Targeting the METTL3 m6A Methyltransferase for Cancer Drug Discovery","authors":"Ziyad Tariq Muhseen, Hussen Hazim Al-Ghanini, Roaa A. Humaidan, Zahraa Yousif Al-Hajjaj, Ola H. Fadhil","doi":"10.1007/s12247-026-11126-4","DOIUrl":"10.1007/s12247-026-11126-4","url":null,"abstract":"<div><h3>Objective </h3><p>To identify novel phytochemical inhibitors of methyltransferase-like 3 (METTL3), a key regulator of N6-methyladenosine (m6A) RNA methylation implicated in cancer development, using an integrated computational drug discovery approach.</p><h3>Methods</h3><p>Five supervised machine learning models were trained using 88 active METTL3 inhibitors and 440 inactive decoy compounds. The best-performing models were used to screen 2,347 phytochemicals from the MPD3 library, followed by consensus-based candidate selection and Lipinski’s Rule of Five filtering. Molecular docking was performed against the METTL3 co-crystal structure (PDB: 9G4S), followed by absorption, distribution, metabolism, excretion, and toxicity (ADMET) profiling. Three selected compounds underwent 100 ns all-atom molecular dynamics (MD) simulations, with complex stability assessed using root-mean-square deviation (RMSD), root-mean-square fluctuation (RMSF), hydrogen-bonding analysis, principal component analysis (PCA), and trajectory snapshots. Molecular mechanics generalized Born surface area (MM-GBSA) calculations were performed to estimate binding free energies.</p><h3>Results</h3><p>Random Forest (area under the receiver operating characteristic curve [AUC] = 0.917) and Gradient Boosting (AUC = 0.911) demonstrated the highest predictive performance. Consensus screening identified 75 high-probability candidates. Molecular docking revealed five top-ranked compounds with scores ranging from −10.0 to −11.3 kcal/mol, demonstrating interactions with key catalytic residues, including Asp395, His512, Asn549, and Gln550. Following ADMET assessment, PubChem637406 and PubChem162892281 were excluded due to predicted AMES mutagenicity. MD simulations indicated that PubChem31553 and PubChem5280704 maintained stable interactions within the METTL3 S-adenosylmethionine (SAM)-binding pocket, whereas PubChem11669392 exhibited unstable interactions and eventually dissociated from the active site. MM-GBSA calculations yielded estimated binding free energies of −28.70 ± 5.91 kcal/mol for PubChem31553 and −27.23 ± 3.26 kcal/mol for PubChem5280704, comparable to the reference inhibitor (−27.93 ± 2.35 kcal/mol). In contrast, PubChem11669392 exhibited a less favorable estimated binding free energy of −13.70 ± 3.19 kcal/mol.</p><h3>Conclusions</h3><p>The integrated computational screening workflow identified PubChem31553 and PubChem5280704 as promising candidate scaffolds for METTL3 inhibition, supported by favorable docking scores, stable MD trajectories, and estimated binding free energies comparable to those of the reference inhibitor. These findings provide a foundation for experimental validation of these compounds and their potential development as leads for m6A-targeted anticancer drug discovery. Further biochemical and cellular studies are required to confirm their inhibitory activity, selectivity, and therapeutic potential.</p></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"22 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149189893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nisha Agari Bhatt, Ashok Behera, Aman Chaudhary, Jhuma Samanta
{"title":"Comparative Development of Separate Sodium Caseinate Nanoparticle Formulations of 5-Fluorouracil and 5-Fluorouracil-1-acetic Acid: Physicochemical, In Vitro, and Ex Vivo Evaluation","authors":"Nisha Agari Bhatt, Ashok Behera, Aman Chaudhary, Jhuma Samanta","doi":"10.1007/s12247-026-11119-3","DOIUrl":"10.1007/s12247-026-11119-3","url":null,"abstract":"<div><h3>Purpose</h3><p>This study aimed to develop and optimize separate sodium caseinate nanoparticles containing 5-fluorouracil (5-FU) and 5-fluorouracil-1-acetic acid (5-FUA), and to evaluate their properties.</p><h3>Methods</h3><p>Nanoparticles were prepared using calcium-ion-induced crosslinking. Separate three-factor, three-level Box–Behnken designs were used to optimize CAS-5FU and CAS-5FUA nanoparticles using entrapment efficiency and drug loading as responses. Formulations were characterized for particle size, polydispersity index, zeta potential, drug release, serum stability, antioxidant activity, hemocompatibility, ex vivo intestinal permeation, and HeLa-cell cytotoxicity.</p><h3>Results</h3><p>The optimized CAS-5FU and CAS-5FUA nanoparticles showed entrapment efficiencies of 94.70% and 28.46%, respectively, and drug-loading values of 57.00% and 15.65%, respectively. Mean particle sizes were 210 ± 12 and 195 ± 10 nm, with PDIs of 0.26 ± 0.03 and 0.24 ± 0.02, respectively. CAS-5FU nanoparticles produced a 1.42-fold higher cumulative permeated amount per unit intestinal surface area than free 5-FU (14.52 versus 10.25 µg/cm²) under these conditions. CAS-5FUA nanoparticles did not enhance permeation compared with free 5-FUA (12.5 versus 13.5 µg/cm²). Both formulations exhibited prolonged, pH-dependent release, short-term serum physicochemical stability, and less than 5% hemolysis. CAS-5FU showed greater chemical radical-scavenging activity than CAS-5FUA. Both formulations produced concentration-dependent reductions in HeLa-cell viability, with estimated IC₅₀ values of approximately 250 and 240 µM, respectively.</p><h3>Conclusion</h3><p>CAS-5FU nanoparticles showed higher entrapment efficiency, drug loading, cumulative ex vivo permeation, and chemical radical-scavenging activity than CAS-5FUA nanoparticles. The results confirm their potential as nanocarriers, but more comparative and in vivo studies are needed.</p><h3>Graphical Abstract</h3><div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"22 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149189822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ashwin Ravichandran, Aishwarya Reddy, Sai Varshini Magham, Avinash Kumar, Pravallika P
{"title":"VEGF-binding V7t1 Aptamer Conjugate for Dual Modulation of Angiogenesis and MMP-2 in CRC","authors":"Ashwin Ravichandran, Aishwarya Reddy, Sai Varshini Magham, Avinash Kumar, Pravallika P","doi":"10.1007/s12247-026-11115-7","DOIUrl":"10.1007/s12247-026-11115-7","url":null,"abstract":"<div><h3>Background</h3><p>Colorectal cancer (CRC) ranks among the leading causes of cancer-related mortality worldwide, with lifestyle factors such as poor diet, high red meat consumption, and physical inactivity contributing to its incidence. Conventional chemotherapeutic agents, including 5-fluorouracil, irinotecan, and oxaliplatin, have limitations associated with non-targeted action and systemic adverse effects. Consequently, precision medicine approaches targeting molecular pathways involved in tumor growth and metastasis have gained considerable attention. Matrix metalloproteinase-2 (MMP-2) plays a pivotal role in tumor invasion and angiogenesis and is markedly overexpressed in CRC.</p><h3>Objective</h3><p>This review discusses the potential of targeting MMP-2 using doxycycline and the application of the V7t1 DNA aptamer as a VEGF-targeting ligand for developing a targeted therapeutic strategy against CRC.</p><h3>Methods</h3><p>Published literature concerning MMP-2 in CRC, the MMP-inhibitory activity of doxycycline, V7t1 DNA aptamer-mediated targeting, VEGF, angiogenesis, metastasis, and targeted drug delivery was reviewed and critically evaluated. Available in silico and preclinical findings relevant to the proposed therapeutic approach were also considered.</p><h3>Results</h3><p>Doxycycline, a tetracycline antibiotic with reported MMP-inhibitory activity, represents a potential drug-repurposing strategy rather than an approved anticancer indication. Its MMP-modulating activity may involve metal-ion chelation as well as effects on MMP expression and pro-MMP activation. The V7t1 DNA aptamer has demonstrated specificity toward VEGF, particularly VEGF121 and VEGF165, and may facilitate targeted delivery. Published in silico studies have reported favorable interactions between V7t1 and VEGF, while preclinical studies have indicated selective inhibition of cancer cell proliferation and angiogenesis with comparatively limited effects on normal cells. The proposed therapeutic system, designated DH–V7t1, is a direct aptamer conjugate in which V7t1 serves as the VEGF-targeting ligand and doxycycline hyclate provides MMP-inhibitory activity. These mechanisms are distinct but potentially complementary and may improve therapeutic selectivity and efficacy.</p><h3>Conclusion</h3><p>The DH–V7t1 system represents a proposed preclinical therapeutic concept for combining VEGF-targeted delivery with MMP inhibition in CRC. However, its conjugation efficiency, structural integrity, release behavior, targeting ability, pharmacokinetics, biodistribution, safety, and therapeutic efficacy require experimental validation before its translational potential can be established.</p><h3>Graphical Abstract</h3><div><figure><div><div><picture><source><img></source></picture></div><div><p>Proposed mechanism of action of the DH–V7t1 aptamer conjugate in CRC</p></div></div></figure></div></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"22 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149189823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Manufacturing Readiness and Route Reconfiguration in Therapeutic Radiopharmaceutical Development: A Multiple-Case Process Study","authors":"Soon Kyu Jung, Sang-Won Lee","doi":"10.1007/s12247-026-11129-1","DOIUrl":"10.1007/s12247-026-11129-1","url":null,"abstract":"<div><h3>Purpose</h3><p>Therapeutic radiopharmaceuticals require isotope procurement, radiolabeling, quality control, transport, and patient administration to be coordinated within time windows constrained by radioactive decay. This study examines how manufacturing readiness develops as manufacturing routes are established and reconfigured across clinical development and commercialization, distinguishing access to a manufacturing route from product-specific preparation and documented product-level use.</p><h3>Methods</h3><p>A multiple-case process study analyzed 14 therapeutic radiopharmaceutical product cases and 51 documented events identified through August 1, 2026. Thirty-six events were directly linked to a specific product. Twelve cases with at least two product-related events formed the core comparative sample. Within-case timelines, cross-case comparison, and sequence and interval analysis were used to examine manufacturing access, product-specific readiness, actual production/supply, route addition, and supply-status changes.</p><h3>Results</h3><p>Four cases showed product-related manufacturing or supply events 89–683 days before entry into clinical development. In four cases, company-level facilities were used for actual production/supply 62–1,348 days after they were secured. Nine cases recorded 14 manufacturing or supply changes 174–3,977 days after entry into clinical development. In-house, regional, and external routes were added in different sequences, including among products using the same radionuclide. Post-approval observations also distinguished site approval, production interruption, restart, and shortage resolution as separate events.</p><h3>Conclusion</h3><p>Manufacturing readiness in therapeutic radiopharmaceutical development is better understood as a product–route process than as a binary firm-level capability. A contract or facility creates manufacturing access, but product-specific preparation and documented use may occur later, and the process may recur when routes are added during development or commercialization.</p><h3>Summary</h3><p>This study reconstructs how therapeutic radiopharmaceutical manufacturing routes were established, connected to product-level use, and expanded across development. Fourteen cases and 51 documented events show that facility or contract access did not automatically coincide with product-level use. In four cases, securing a company-level facility and actual production/supply at that facility were separated by 62–1,348 days, while manufacturing changes continued years after entry into clinical development. The findings support a product–route view of manufacturing readiness and distinguish structural route availability from operational usability.</p><h3>Teaser</h3><p>Manufacturing access does not ensure product-level readiness: therapeutic radiopharmaceutical routes become operational through product-specific preparation, documented use, and route reconfiguration across clinical developmen","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"22 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149189824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Formulation and Evaluation of Oral Anti-IL-1β IgY-Loaded Nanoliposomes in DSS-Induced Colitis","authors":"Guiying Dai, Wenjing Xu, Youdan Sun, Xiaoyan Zheng, Changsheng Chen, Fang Gan, Yunhuan Liu, Xinyi Xu, Sichao Mao, Xingxiang Chen","doi":"10.1007/s12247-026-11127-3","DOIUrl":"10.1007/s12247-026-11127-3","url":null,"abstract":"<div><h3>Purpose</h3><p>To develop an oral nanoliposomal formulation of anti-interleukin-1β (IL-1β) immunoglobulin Y (IgY) and evaluate its physicochemical properties, gastric stability, and activity in dextran sulfate sodium (DSS)-induced colitis.</p><h3>Methods</h3><p>Recombinant canine IL-1β was expressed and used to immunize hens. Purified IgY was loaded into 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC)/cholesterol nanoliposomes by thin-film hydration. Encapsulation efficiency, particle characteristics, morphology, and residual IgY antigen-binding activity in simulated gastric fluid were assessed. Male Institute of Cancer Research (ICR) mice with DSS-induced colitis received free IgY, empty liposomes, or IgY-loaded nanoliposomes. Disease activity, organ indices, colonic cytokines, histopathology, and Occludin and ZO-1 expression were evaluated.</p><h3>Results</h3><p>The IgY showed a maximum endpoint titer of 1:409,600, recognized recombinant canine IL-1β, and showed detectable cross-reactivity with recombinant murine IL-1β by Western blotting. Nanoliposomes achieved approximately 56% encapsulation efficiency, a polydispersity index of approximately 0.35, negative ζ-potential, and intact vesicular morphology. At 150 min in simulated gastric fluid, two parallel samples from the same liposomal preparation retained 43.96% and 35.98% antigen-binding activity, respectively. In DSS-treated mice, the formulation was associated with improved clinical indices, lower colonic IL-1β, IL-6, and TNF-α levels, less histopathological injury, and recovery of barrier-protein staining.</p><h3>Conclusion</h3><p>Nanoliposomal encapsulation improved the in vitro gastric stability of anti-IL-1β IgY and was associated with anti-inflammatory and barrier-protective effects in DSS-induced experimental colitis. Western blotting demonstrated detectable cross-reactivity of the anti-canine IL-1β IgY with recombinant murine IL-1β; however, functional neutralization of murine IL-1β was not directly assessed.</p><h3>~ 100 Word Summary Anti-IL-1β IgY </h3><p>is a potential oral antibody strategy for intestinal inflammation, but gastric instability limits its use. In this study, IgY raised against recombinant canine IL-1β was incorporated into DSPC/cholesterol nanoliposomes and evaluated for physicochemical properties, simulated gastric stability, and activity in DSS-induced colitis. The formulation achieved approximately 56% encapsulation efficiency and retained substantially more IgY antigen-binding activity than free IgY during gastric exposure. In mice, IgY-loaded nanoliposomes were associated with improved disease indices, reduced colonic cytokines, less histopathological injury, and recovery of Occludin and ZO-1 staining. These findings support nanoliposomal protection of IgY during oral delivery, and detectable cross-reactivity with recombinant murine IL-1β was further confirmed by Western blotting.</p><h3>25–30 Word Teaser </h3><p>Nanoliposomal encapsulation improve","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"22 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149189290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Three-Dimensional SiHa Tumor Spheroids for Evaluating Berberis aquifolium-Loaded Chitosan Nanoparticles in Cervical Cancer","authors":"Aadipoojya Jain, Deepika Sharma, Areena Turk, Tejveer Singh","doi":"10.1007/s12247-026-11110-y","DOIUrl":"10.1007/s12247-026-11110-y","url":null,"abstract":"<div><h3>Objective</h3><p>The present study aims to develop a chitosan nanoparticle-based delivery system encapsulating <i>Berberis aquifolium</i> (BA) extract to evaluate its anticancer activity against cervical cancer cells using conventional two-dimensional (2D) cultures and three-dimensional (3D) tumor spheroids models.</p><h3>Methods</h3><p><i>Berberis aquifolium</i>-loaded chitosan nanoparticles (BCNPs) were prepared using ionic gelation with sodium tripolyphosphate and characterized for hydrodynamic particle size, polydispersity index (PDI), zeta potential, and morphology. extract was encapsulated in chitosan nanoparticles using an appropriate nanoformulation technique. The anticancer activity of the BCNPs was evaluated in SiHa cervical cancer cells using the MTT assay. A 3D SiHa spheroid model was established and used to assess treatment-associated changes in spheroids morphology and structural integrity.AO/EtBr staining was used for qualitative assessment of cell viability and morphological changes. The response of primary goat hepatocytes and testicular cells to the formulation was also evaluated as an initial assessment of its effects on non-cancerous cells.</p><h3>Results</h3><p>BCNPs showed an average hydrodynamic diameter of 399.9 nm, PDI of 0.20, and zeta potential of -41.1 mV, compared with 413.2 nm, 0.30, and − 17.0 mV, respectively, for blank chitosan nanoparticles. The nanoparticles exhibited predominantly spherical morphology. BCNPs treatment produced a concentration-dependent reduction in SiHa cell viability, with an IC50 of 350 µg/mL. In the 3D spheroid model, BCNPs treatment progressively disrupted spheroid structure, with complete spheroid disintegration observed at 750 µg/mL. AO/EtBr staining showed loss of cell viability and morphological features suggestive of apoptosis.</p><h3>Conclusions</h3><p>The study demonstrated the successful development of BCNPs with anticancer activity against SiHa cervical cancer cells in both 2D and 3D models. The 3D spheroid model provided complementary information on treatment-associated changes in tumor-like spheroid structure and viability, supporting its utility for evaluating the anticancer activity of BCNPs. Further mechanistic and in vivo studies are required to establish their therapeutic potential.</p></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"22 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149189056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ali Alquraini, Mohammed Alahmari, Faisal K Alkholifi, Yahia Alghazwani, Marwa Qadri, Fadhel A. Alomar, Daniyah A. Almarghalani, Mohd Imran
{"title":"Machine Learning-Guided Discovery of Potential Natural KRAS-G12D Inhibitors for Pancreatic Carcinoma","authors":"Ali Alquraini, Mohammed Alahmari, Faisal K Alkholifi, Yahia Alghazwani, Marwa Qadri, Fadhel A. Alomar, Daniyah A. Almarghalani, Mohd Imran","doi":"10.1007/s12247-026-11123-7","DOIUrl":"10.1007/s12247-026-11123-7","url":null,"abstract":"<div><h3>Background</h3><p>The mutation KRAS-G12D found in pancreatic cancer is one of the biggest barriers to developing targeted therapy against pancreatic cancer. This research work tries to discover the potential KRAS-G12D inhibitors through natural products guided by machine learning approaches.</p><h3>Methods</h3><p>The screening process involved a library of 3,634 natural compounds sourced from the SelleckChem database, which were then filtered using the established QSAR model. Among these compounds, 176 potential compounds with appropriate predicted activities (pIC50) were chosen for subsequent testing. The 176 compounds were then docked against the switch-II pocket of the KRAS-G12D mutant protein. Compounds exhibiting docking scores equal to or lower than that of the reference inhibitor MRTX1133 (− 8.9 kcal/mol) were selected for subsequent ADMET and molecular dynamics analyses. The potential candidates were analyzed for their ADMET properties and binding interactions in silico. Further validation of the selected compounds was done by performing a molecular dynamics simulation for 300 ns along with a reference compound.</p><h3>Results</h3><p>KR1 and KR2 compounds were observed to have stable binding to the KRAS-G12D protein with RMSD values between 0.18 nm and 0.25 nm. MM-GBSA binding free energy calculations revealed a favorable interaction with energy levels of -13.57 kcal/mol and − 20.48 kcal/mol, respectively. The DFT analysis revealed that KR1 is more chemically stable due to high HOMO-LUMO gap values (4.669 eV) and low electrophilicity values (0.92 eV). However, KR2 was found to have balanced reactivity properties, with a relatively high electronegativity value (3.537 eV) and ionization potential value (4.828 eV).</p><h3>Conclusion</h3><p>Overall, these computations support the potential of KR1 and KR2 as valuable potential lead compounds of KRAS-G12D. Clearly, these results provide a robust basis for subsequent experimentation to validate their biological effects and therapeutic potential.</p></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"22 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149189252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}